PMID- 29873998
OWN - NLM
STAT- MEDLINE
DCOM- 20180626
LR  - 20180626
IS  - 0869-2092 (Print)
IS  - 0869-2092 (Linking)
VI  - 80
IP  - 1
DP  - 2017
TI  - [HYPOLIPIDEMIC, ANTIOXIDANT, AND ENDOTHELIAL PROTECTIVE EFFECT OF COMPOUND ZB-16 
      (NOVEL GPR119 RECEPTOR AGONIST) IN RATS WITH EXPERIMENTAL TYPE 2 DIABETES.].
PG  - 18-23
AB  - The effect of compound ZB-16 (a new GPR1 19 receptor agonist) after two-week 
      administration on the endothelial function, glucose and lipid metabolism (total 
      cholesterol, LDL, HDL and triglycerides), lipid peroxidation, and antioxidant 
      system status in rats with experimental type-2 diabetes mellitus (T2DM) has been 
      studied. It was found that the untreated control group of animals exhibited, in 
      addition to sustained hyperglycemia, a decrease in endothelium-dependent vaso- 
      dilation and antioxidant system activity, and increase in the content of LDL and 
      the dyslipidemic index. Administration of ZB-16 (1 mg/kg, p.o.) in rats with T2DM 
      model resulted in reduction of the endothelial dysfunction (improved 
      endothelium-dependent vasodilation by 83% as compared to the control group, p < 
      0.05). ZB-16 also produced a moderate antioxidant effect of reducing the content 
      of TBA-active products (by 30% as compared to the untreated control, p <0.05) and 
      favored normalization of lipid metabolism indicators.
FAU - Tyurenkovl, I N
AU  - Tyurenkovl IN
FAU - Kurkin, D V
AU  - Kurkin DV
FAU - Bakulin, D A
AU  - Bakulin DA
FAU - Volotova, E V
AU  - Volotova EV
FAU - Shafeev, M A
AU  - Shafeev MA
LA  - rus
PT  - Journal Article
PL  - Russia (Federation)
TA  - Eksp Klin Farmakol
JT  - Eksperimental'naia i klinicheskaia farmakologiia
JID - 9215981
RN  - 0 (Antioxidants)
RN  - 0 (Blood Glucose)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (GPR119 protein, rat)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Piperidines)
RN  - 0 (Pyrimidines)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 0 (Thiobarbituric Acid Reactive Substances)
RN  - 0 (Triglycerides)
RN  - 5W494URQ81 (Streptozocin)
SB  - IM
MH  - Animals
MH  - Antioxidants/*pharmacology/therapeutic use
MH  - Blood Glucose/drug effects/metabolism
MH  - Cell Count
MH  - Cholesterol, HDL/blood
MH  - Cholesterol, LDL/blood
MH  - Diabetes Mellitus, Experimental/blood/chemically induced/*drug therapy/genetics
MH  - Dyslipidemias/blood/chemically induced/*drug therapy/genetics
MH  - Endothelial Cells/drug effects
MH  - Female
MH  - Gene Expression/drug effects
MH  - Hypoglycemic Agents/*pharmacology/therapeutic use
MH  - Hypolipidemic Agents/*pharmacology/therapeutic use
MH  - Lipid Metabolism/drug effects
MH  - Lipid Peroxidation/drug effects
MH  - Piperidines/*pharmacology/therapeutic use
MH  - Pyrimidines/*pharmacology/therapeutic use
MH  - Rats
MH  - Receptors, G-Protein-Coupled/*agonists/genetics/metabolism
MH  - Streptozocin
MH  - Thiobarbituric Acid Reactive Substances/metabolism
MH  - Triglycerides/blood
MH  - Vasodilation/drug effects
EDAT- 2017/01/01 00:00
MHDA- 2017/01/01 00:01
CRDT- 2018/06/07 06:00
PHST- 2018/06/07 06:00 [entrez]
PHST- 2017/01/01 00:00 [pubmed]
PHST- 2017/01/01 00:01 [medline]
PST - ppublish
SO  - Eksp Klin Farmakol. 2017;80(1):18-23.